Compare Cytokinetics Inc (CYTK) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs LyondellBasell Industries NV — how do they compare? Cytokinetics Inc trades at $62.1 (market cap $8.62B), while LyondellBasell Industries NV trades at $60.27 (market cap $19.49B). The key difference: LyondellBasell Industries NV is far larger — about 2.3× Cytokinetics Inc's market cap, and LyondellBasell Industries NV pays a 4.57% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and LyondellBasell Industries NV for 87 Days on average.
| CYTK | LYB | |
|---|---|---|
Market Cap | $8.62B | $19.49B |
Volume | 2,594,626 | 6,033,396 |
Sector | Health | Basic Materials |
52-Week High | $87.26 | $82.38 |
52-Week Low | $54.76 | $42.28 |
Typical Hold Time | 19 Days | 87 Days |
Enterprise Value | $8.72B | $31.08B |
Dividend Yield | — | 4.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
LyondellBasell (LYB) trades at $58.49, down 0.75% on the day, with a bearish technical signal and mixed fundamentals. Recent earnings show volatility, with a Q2 2026 beat but a net loss for 2025. Revenue has declined from $50.5B in 2022 to $30.2B in 2025, though 2026 projects a slight recovery. The stock offers a dividend, but news highlights concerns over dividend sustainability amid sector challenges.
Outlook is cautious; analyst consensus is split with a $69.38 price target suggesting upside, but profitability metrics are weak. Key risks include persistent negative margins, high debt, and chemical sector cyclicality. Investment opportunity hinges on operational turnaround and market recovery, but near-term headwinds prevail.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
